Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marta Canta

Showing results (11-20 of 12) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 12 results.
BMC Cancer|May 9, 2015
The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesotheliomaYmera Pignochino, Carmine Dell'Aglio, Simona Inghilleri, et al.
Molecular Cancer|April 30, 2017
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical modelsYmera Pignochino, Federica Capozzi, Lorenzo D'Ambrosio, et al.
Pageof 2

Showing results (11-20 of 12) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 12 results.
BMC Cancer|May 9, 2015
The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesotheliomaYmera Pignochino, Carmine Dell'Aglio, Simona Inghilleri, et al.
Molecular Cancer|April 30, 2017
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical modelsYmera Pignochino, Federica Capozzi, Lorenzo D'Ambrosio, et al.
Pageof 2